Cargando…
An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome
BACKGROUND: A recombinant form of antithrombin (AT), called AT gamma, is being developed as an alternative to AT derived from human plasma. To compare the efficacy and safety of AT gamma to plasma-derived AT (pAT), we conducted a randomized, open-label, multicenter trial in patients with sepsis-indu...
Autores principales: | Endo, Shigeatsu, Shimazaki, Ryutaro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240214/ https://www.ncbi.nlm.nih.gov/pubmed/30473794 http://dx.doi.org/10.1186/s40560-018-0339-z |
Ejemplares similares
-
A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis
por: Gando, Satoshi, et al.
Publicado: (2013) -
Impact of Antithrombin Activity Levels Following Recombinant Antithrombin Gamma Therapy in Patients with Sepsis-Induced Disseminated Intravascular Coagulation
por: Akahoshi, Tomohiko, et al.
Publicado: (2022) -
Efficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation
por: Iba, Toshiaki, et al.
Publicado: (2014) -
Comparison of Protective Effects of Recombinant Antithrombin Gamma
and Plasma-Derived Antithrombin on Sepsis-Induced Disseminated Intravascular
Coagulation and Multiple Organ Failure
por: Kuroda, Hiromitsu, et al.
Publicado: (2020) -
Antithrombin III concentrate may contribute to sepsis in nonovert disseminated intravascular coagulation
por: Saito, Noriko, et al.
Publicado: (2013)